Peregrine flying high as CMO biz preps to open new mAb facility

By Dan Stanton

- Last updated on GMT

Peregrine's CMO subsidiary, Avid Bioservices, is located in Tustin, California
Peregrine's CMO subsidiary, Avid Bioservices, is located in Tustin, California

Related tags Lung cancer

Avid Bioservices' expansion will double existing capacity to service both a $40m backlog and its owner Peregrine, which is hoping to commercialise its breast cancer candidate.

Peregrine Pharmaceuticals saw revenues grow 20% y-o-y, mostly due to its contract manufacturing subsidiary Avid Biosciences which reported total sales of $27m (€25m) for the fiscal year 2015.

During a conference call discussing these results Tuesday, management said there was a committed backlog of $40m from existing customers, much of which will be carried out at a new mammalian cell culture facility in California set to come online in the next few months.

Last December​, we laid out strategic plans to expand our manufacturing capacity to help support the revenue growth of Avid,”​ said CFO Paul Lytle. “I am excited to say that the new facility is close to being ready for production​.

“The core manufacturing suite has been built, the equipment has been installed, and it is now undergoing some final testing to ensure all systems are operating effectively,”​ he told investors. “We remain on track to commence production in this new facility in the very near future.”

While the investment will service its customers, the facility has also been built in preparation of a commercial launch of Peregrine’s own lead candidate bavituximab a monoclonal antibody (mAb) for non-small cell lung cancer (NSCLC), a Phase III trial blinded, randomized trial of which is on track to end enrolment by the end of the year.

The new facility was described as a “pivotal event”​ in the growth of Avid and potential commercialization of bavituximab by CEO Steve King during the call, who added there would be “a nice mix”​ between in-house and customer utilization.

Related topics Bio Developments Facilities

Related news

Show more

Related products

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Related suppliers

Follow us


View more